Key Highlights

  • Net loss was USD 6.58 million, compared with USD 3.04 million.
  • Loss per share was USD 0.20, compared with USD 0.41.
  • Research and development expenses were USD 4.46 million, compared with USD 1.36 million.
  • Cash and cash equivalents were USD 41.22 million at September 30, 2026.

Pasithea Therapeutics (NASDAQ:KTTA) reported a net loss of USD 6.58 million for the third quarter of 2026, compared with USD 3.04 million in the prior-year quarter. Basic and diluted loss per share was USD 0.20, compared with USD 0.41.

For the nine months ended September 30, 2026, the net loss was USD 14.72 million, compared with USD 10.32 million, and loss per share was USD 0.49, compared with USD 2.02.

Operating Expenses

Research and development expenses were USD 4.46 million, compared with USD 1.36 million, and general and administrative expenses were USD 2.51 million, compared with USD 1.75 million. The loss from operations was USD 6.97 million, compared with USD 3.11 million.

Other income, net, was USD 390 thousand, compared with USD 73 thousand, including net interest and dividends of USD 371 thousand, compared with USD 43 thousand. The change in Fair Value of Warrant liabilities was USD 32 thousand, compared with USD 47 thousand. Weighted average shares outstanding were 33,414,448, compared with 7,443,577.

Nine-Month Results

For the nine months, Research and Development expenses were USD 11.09 million, compared with USD 5.24 million, and general and administrative expenses were USD 6.47 million, compared with USD 5.36 million. The loss from operations was USD 17.56 million, compared with USD 10.60 million, and other income, net, was USD 2.84 million, compared with USD 284 thousand.

Balance Sheet and Clinical Programs

Cash and cash equivalents were USD 41.22 million at September 30, 2026, compared with USD 55.16 million at December 31, 2025. Total Assets were USD 46.49 million, compared with USD 60.24 million, and total liabilities were USD 2.76 million, compared with USD 5.02 million.

The filing states that the company's ongoing Phase 1 open-label, dose escalation trial of PAS-004 began in December 2023 in patients with MAPK pathway-driven advanced tumors, and that a Phase 1/1b trial in adult patients with NF1 and symptomatic, inoperable or recurrent plexiform neurofibromas began in May 2025. The filing also states that the FDA cleared the company's Investigational New Drug application for a randomized, placebo-controlled Phase 2 trial of PAS-004 in patients with NF1-associated cutaneous neurofibromas.

Prepaid expenses were USD 1.83 million, compared with USD 811 thousand, and restricted cash was USD 102 thousand, compared with USD 101 thousand. The filing reports 33,414,448 shares issued and outstanding at September 30, 2026, compared with 23,091,062 at December 31, 2025.

The filing states that, in connection with the Acquisition of Alpha-5, the company legally assumed rights under a grant agreement with FightMND, entered into on September 23, 2021. Under the grant agreement, the company is entitled to reimbursements for costs incurred for research related to its monoclonal antibody targeting a5b1 integrin as a potential treatment for amyotrophic lateral sclerosis.

Pasithea Therapeutics Q3 2026 Earnings: Key Takeaways

Pasithea Therapeutics reported a third quarter 2026 net loss of USD 6.58 million and a loss per share of USD 0.20. Cash and cash equivalents were USD 41.22 million at September 30, 2026.